New product: Cosentyx (secukinumab) 150 mg solution for injection

Secukinumab is licensed for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. It is administered subcutaneously at a dose of 300mg (2 injections of 150mg) on weeks 0, 1, 2 and 3, followed by monthly maintenance dosing.

 

NICE is currently appraising the use of secukinumab for treating moderate to severe plaque psoriasis in people for whom other systemic therapies have been inadequately effective, not tolerated or contraindicated. Final guidance is due to be issued in July 2015.